In a phase 2b RCT of 84 children aged 2-11 with achondroplasia, weekly navepegritide increased annualised growth velocity at week 52 vs placebo (difference 1.49 cm/y). Secondary skeletal measures improved; no treatment-related serious adverse events.
RCTn = 84
Savarirayan et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial